Catalyst Wire Dossier Catalyst Wire Dossier

Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells

TGFBR2 knockout CD70 CAR NK cells · The University of Texas MD Anderson Cancer Center
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells, covering 2025-10-07 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma [Phase 1]

See pricing